<DOC>
	<DOCNO>NCT00672321</DOCNO>
	<brief_summary>RATIONALE : Gathering information vitamin D supplementation sun exposure patient melanoma may help doctor learn disease find may affect cancer relapse . PURPOSE : This clinical trial study vitamin D supplementation sun exposure patient undergone surgery stage IB , stage II , stage IIIA melanoma .</brief_summary>
	<brief_title>Answering Questions About Vitamin D Supplementation Sun Exposure Patients Who Have Undergone Surgery Stage IB , Stage II , Stage IIIA Melanoma</brief_title>
	<detailed_description>OBJECTIVES : - To examine finding pilot study , vitamin D supplementation combination vitamin D receptor ( VDR ) polymorphisms protects late relapse ( 3 year ) patient melanoma . - To investigate effect vitamin D supplement dosage reduce risk late relapse . - To examine vitamin D supplementation combination particular VDR polymorphism protect early relapse ( 3 year ) . - To examine serum level vitamin D correlate risk relapse group patient different VDR polymorphism . - To examine effect vitamin supplementation VDR status time relapse survival patient . - To examine factor may affect risk relapse assemble tissue ( genomic DNA serum ) resource . - To investigate effect exposure incidental drug , statin , risk relapse patient . OUTLINE : Patients stratify accord disease relapse past 5 year ( yes v ) . Patients ask complete food frequency questionnaire focus vitamin D follow area : supplementation diet vitamins/fish oil duration use ; sun exposure sunscreen-use per decade prior diagnosis . Patients also ask provide blood sample serum DNA analysis . Consenting patient also tag Office National Statistics allow passive follow . Stored tissue patient 's primary melanoma may use corroborate research finding use immunohistochemistry study gene expression , polymorphism , mutation .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosed melanoma Must meet either follow condition : Resected stage IB , II , IIIA disease relapse either stage III IV disease ( case ) First loco regional and/or visceral relapse ( with/without sentinel node biopsy ) No 3 month since first relapse Resected stage IB , II , IIIA disease relapse â‰¥ 5 year ( control ) PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>recurrent melanoma</keyword>
	<keyword>stage IB melanoma</keyword>
	<keyword>stage II melanoma</keyword>
	<keyword>stage IIIA melanoma</keyword>
</DOC>